Condoliase

Summary

Condoliase (CHEMBL2107876) is a phase-3 clinical-stage enzyme.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107876
Name	Condoliase
Type	Enzyme
Max phase	3

Also known as: Condoliasa, Condoliase, Hernicore, SI-6603, CONDOLIASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00634946	PHASE2/PHASE3	COMPLETED	SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation
NCT01941563	PHASE3	COMPLETED	A Study of SI-6603 in Patients With Lumbar Disc Herniation
NCT02421601	PHASE3	COMPLETED	A Study of SI-6603 in Patients With Lumbar Disc Herniation
NCT03607838	PHASE3	COMPLETED	SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
NCT01282606	PHASE2	COMPLETED	Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).